Schrödinger (SDGR) Q2 2026 earnings review
ACV Accelerates, But Headline 'Profit' is a Mirage
Schrödinger's Q2 results highlight a massive optical disconnect. The underlying software business is accelerating, with Annual Contract Value (ACV) surging 27% YoY to $29.6M. However, because the company is aggressively transitioning to a hosted SaaS model, upfront revenue recognition is collapsing—driving a 10% YoY drop in reported Software Revenue. Meanwhile, headline Net Income turned positive ($6.0M), but this was entirely manufactured by a $45.9M non-operating gain from Eli Lilly's acquisition of Ajax Therapeutics. Operating losses remain deep at $41.5M. The core SaaS transition is working, but the GAAP financials look incredibly messy.
🐂 Bull Case
ACV growth accelerated to 27% (and 23% excluding contribution revenue). Hosted revenue is now 47% of total software revenue, building a highly predictable, recurring revenue engine for the future.
The Lilly/Ajax acquisition triggered a $10M milestone, pushing Drug Discovery revenue up 65% YoY to $23M and prompting a full-year guidance raise. The partnered model continues to validate the platform's scientific moat.
🐻 Bear Case
The hosted transition is cannibalizing optical growth. Software revenue fell 10% YoY, and Software Gross Margins compressed to 71% (down from historical ~80% levels).
Headline net income is highly misleading. Stripping out the one-time equity gain from the Ajax deal, the company generated an operating loss of $41.5M. Profitability is entirely dependent on lumpy, unpredictable biotech M&A.
⚖️ Verdict: ⚪
Neutral. The underlying ACV growth and the launch of the Bunsen AI tool are strong bullish signals for the platform's relevance. However, investors must look past ugly GAAP revenue and margin compression during this multi-year SaaS transition. The optical noise will keep conservative money on the sidelines.
Key Themes
Bunsen AI Co-Scientist Drives Platform Scale
Schrödinger officially launched the early access version of 'Bunsen', an agentic AI co-scientist built on its physics-based platform. Crucially, they simultaneously announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy it. Because Schrödinger charges based on throughput (compute utilization), Bunsen's ability to automate complex workflows and allow chemists to run concurrent sessions is a massive structural catalyst for future software ACV expansion.
Earnings Quality: Operating vs. Net Income
Management's headline notes a $6.0M Net Income compared to a $43.2M loss a year ago. This contradicts the true operational narrative. Operating expenses were $74.0M against a gross profit of only $32.4M, resulting in a GAAP operating loss of $41.5M. The 'profit' is exclusively due to a $48.9M 'Other Income' bump, largely from the mark-to-market gain on their ~6% stake in Ajax Therapeutics following its acquisition by Eli Lilly. Relying on equity markups is not a sustainable path to operational profitability.
SaaS Transition Accelerating
The deliberate shift to hosted software licensing is moving incredibly fast. Hosted revenue made up 47% of total software revenue in Q2, up from 34% in Q1 and 23% in late 2025. While this ratable revenue recognition model punishes current-quarter GAAP software revenue (-10% YoY) and suppresses gross margins (down to 71%), it is driving the 27% ACV growth and sets up a much higher-quality, recurring revenue base long-term.
Drug Discovery Pipeline Monetization
The company's strategy of abandoning independent clinical trials to focus on early-stage discovery partnerships is paying off. Drug discovery revenue surged 65% YoY to $23.0M, driven by a $10M milestone from the Ajax acquisition. This business segment remains lumpy, but the frequent achievement of milestones continues to non-dilutively fund the software platform's R&D.
Contribution Revenue Fading
Contribution revenue dropped 30% YoY to $3.4M (and was down to $0.1M in Q1), reflecting the expiration/timing of Gates Foundation and Gates Ventures grants. Management now has to split out ACV guidance (total vs. 'excluding contribution') to show underlying commercial strength, making the company harder to model and adding unwanted noise to headline metrics.
Biopharma AI Arms Race (Macro)
Management highlighted mounting pressure in the biopharma industry to optimize molecular discovery using AI. Schrödinger is positioning its physics-based simulation data as the critical 'ground-truth' required to train these emerging AI models, forming a defensible moat against generic tech giants entering the biology space.
Other KPIs
Accelerating. Grew 27% YoY. When excluding the noisy contribution revenue segment, ACV still grew 23% to $22.6M. This is the single most important metric proving that underlying customer demand remains robust despite the optical software revenue decline.
Decreased 6% YoY from $79.0M in 25Q2. Reflects the cost-saving initiatives (including the May 2025 RIF) and the strategic pivot away from funding internal clinical trials, keeping the cash burn manageable.
Up slightly from $406.4M in Q1 2026. A highly secure balance sheet that gives the company multi-year runway to complete its SaaS transition without needing to tap the capital markets.
Guidance
Stable. Implies 10-15% growth over 2025. Maintained from prior quarters, signaling confidence in the back-half software renewal cycle (Q4 is historically the largest quarter).
Accelerating. Raised from the previous expectation of $55M - $65M. The $10M bump is a direct result of the milestone achieved via the Eli Lilly/Ajax Therapeutics acquisition.
Accelerating. Compared to $38.3M in Q3 2025 (which included $2.2M of contribution ACV). This implies strong double-digit growth for the core commercial/academic software business going into the fall.
Stable. Maintained prior guidance, reinforcing management's commitment to reaching positive adjusted EBITDA by 2028.
Key Questions
Bunsen Monetization Mechanics
With BMS strategically deploying Bunsen, how exactly will the agentic AI drive throughput-based billing? What is the expected lag between deployment and an observable spike in compute utilization revenue?
Software Margin Floor
Software gross margins dropped to 71% as hosted deployments hit 47% of mix. At what hosted penetration percentage do you expect software gross margins to hit the floor before rebounding toward your historical 80% targets?
Contribution Revenue Baseline
Given the volatility in Gates Foundation grants, what is the assumed long-term run rate for Contribution ACV in your 2028 framework?